Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Shares of Merck (NYSE: MRK) were trading lower on Tuesday. The drop comes as the S&P 500 gained 0.5% and the Nasdaq Composite ...
Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
Key Takeaways Merck shares fell sharply Tuesday morning after the drugmaker's profits and 2025 outlook fell short of ...
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback